Sort
21,453 grants matching “tuberculosis”
Inhibition of Tubercular Mycothiol Pathways
$233,250Rutgers The St Univ Of Nj New Brunswick · R21 · FY2003 · AI
Transcriptional Regulation of Innate T cell fate
$233,250Laurent Gapin · University Of Colorado Denver · R21 · FY2021 · AI
Admin-Core
$233,243Robert A Salata · Case Western Reserve University · U54 · FY2022 · CA
Admin-Core
$233,243Robert A Salata · Case Western Reserve University · U54 · FY2021 · CA
Admin-Core
$233,242Stanton L Gerson · Case Western Reserve University · U54 · FY2024 · CA
Admin-Core
$233,241Robert A Salata · Case Western Reserve University · U54 · FY2023 · CA
A Randomized Trial of a Four Month Moxifloxacin-based Regimen for Treatment of
$233,210Marcus Barreto Conde · Johns Hopkins University · U19 · FY2009 · AI
MCP-1 and susceptibility to active tuberculosis
$233,162Dana-Farber Cancer Institute · R21 · FY2003 · HL
Vanderbilt Infection Pathogenesis and Epidemiology Research Training Program
$233,075Richard T D'aquila · Vanderbilt University · T32 · FY2011 · AI
Borrelia antigen detection assay for urine-based diagnosis of early Lyme disease
$233,063Nira Pollock · Boston Children'S Hospital · R21 · FY2016 · AI
MYCOBACTERIUM TUBERCULOSIS;INDUCED MACROPHAGE SIGNALLING
$233,035University Of California San Francisco · R01 · FY2000 · HL
Clinical Phenotyping: Pediatric HIV and TB Cohort
$232,868Gabriel Anabwani · Botswana Baylor Child/Clincal Ctr/Excell · U54 · FY2018 · AI
Development of Lipid-based Nanoparticle Vaccines Against Mycobacterium tuberculosis
$232,779Chyung-Ru Wang · Northwestern University At Chicago · R21 · FY2017 · AI
Role of Myeloid Derived Suppressor Cells in Mycobacterium tuberculosis(Mtb)Reactivation in HIV-Mtb co-infected Individuals
$232,680Ankita Garg · University Of California, San Diego · R21 · FY2016 · AI
Technology for HIV Prevention Among Vulnerable Men in India
$232,650Matthew James Mimiaga · Fenway Community Health Center · R21 · FY2011 · DA
BIOSYNTHESIS OF THE MYCOBACTERIAL PEPTIDOGLYCAN
$232,604University Of Rochester · R01 · FY2000 · AI
Point-of-care pharmacogenomic testing to optimize isoniazid dosing for tuberculosis prevention
$232,535Jason Randolph Andrews · Stanford University · R21 · FY2022 · AI
Dissection of Mycobacterium tuberculosis Clp protease assembly, activity and regulation
$232,501Karl Robert Schmitz · University Of Delaware · P20 · FY2020 · GM
Mucosal Adjuvant to Induce Multipronged T Cell Immunity to Tuberculosis
$232,500Marulasiddappa Suresh · University Of Wisconsin-Madison · R21 · FY2020 · AI
B12 Autotrophy as a Virulence Mechanism in Infectious Leptospira
$232,500Michael A Matthias · University Of California, San Diego · R21 · FY2016 · AI
In vivo Reporters of Mycobacterium tuberculosis ESX-5 Secretion
$232,500Anna Degraff Tischler · University Of Minnesota · R21 · FY2021 · AI
Lead identification of 1,4-benzoxazines as anti-tuberculosis agents
$232,500Scott G. Franzblau · University Of Illinois At Chicago · R21 · FY2006 · AI
Differential IL-2 Expression by Effector CD8 T cells and Fate Determination
$232,500Vandana Kalia · Seattle Children'S Hospital · R21 · FY2020 · AI
Small molecule inhibitors pantothenate synthesis against M. tuberculosis
$232,500Pavel A Petukhov · University Of Illinois At Chicago · R21 · FY2006 · AI
Distinguishing inflammatory Th17 subsets through using an autoimmune Th17-selective inhibitor
$232,500Zhiheng He · Wake Forest University Health Sciences · R21 · FY2022 · AI